Autolus Therapeutics Presents Clinical Data Updates at the 2025 Tandem Meetings
January 17, 2025 07:00 ET
|
Autolus Therapeutics plc
Autolus Therapeutics Presents Clinical Data Updates at the 2025 Tandem Meetings
CARGO Therapeutics Provides Corporate Update and Anticipated Milestones for 2025
January 10, 2025 08:00 ET
|
Cargo Therapeutics, Inc.
CARGO Therapeutics Provides Corporate Update and Anticipated Milestones for 2025
Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference
January 09, 2025 09:00 ET
|
Lyell Immunopharma, Inc
Accelerating IMPT-314 in large B-cell lymphoma; remain on track to initiate pivotal trial in the 3rd line+ setting in 2025 and expect to initiate a pivotal trial in the 2nd line by early...
Monthly information on share capital and company voting rights
January 08, 2025 16:30 ET
|
Cellectis Inc.
PARIS, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of...
CAR-T Cell Therapy Market Research 2024-2025: Navigating the CAR-T Landscape, Major Players, Recent Approvals, and Pioneering Therapies
January 03, 2025 04:09 ET
|
Research and Markets
Dublin, Jan. 03, 2025 (GLOBE NEWSWIRE) -- The "CAR-T Cell Therapy Market - Market Size, Forecasts, Trials, and Trends, 2025" report has been added to ResearchAndMarkets.com's offering. This...
CAR-T Cell Therapy Market to Surpass USD 188.84 Billion by 2034 at 36.8% during 2025 to 2034 – Report by Polaris Market Research
December 19, 2024 04:47 ET
|
Polaris Market Research & Consulting LLP
New York, USA, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Market Overview The market for CAR-T cell therapy is poised to exhibit a robust CAGR of 36.8% during 2025–2034. The CAR-T cell therapy market size...
CARGO Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
December 17, 2024 08:00 ET
|
Cargo Therapeutics, Inc.
CARGO Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
Cellectis announces the drawdown of the third tranche of €5 million under the credit facility agreement entered with the European Investment Bank (EIB)
December 10, 2024 16:30 ET
|
Cellectis Inc.
NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) (the “Company”), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting
December 09, 2024 21:00 ET
|
Lyell Immunopharma, Inc
Objective response rate (ORR) of 94% and a complete response (CR) rate of 71% demonstrated after IMPT-314 treatment in CAR T-naïve patients with large B-cell lymphoma who had received at least 2 prior...
Monthly information on share capital and company voting rights
December 04, 2024 16:30 ET
|
Cellectis Inc.
PARIS, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting...